Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season

• 2024

  Log in to bookmark this resource.

  Log in
• Ron Dagan; Laura Hammitt; Beatriz Nuñez; Manuel Cots; Miroslava Bosheva; Shabir Madhi
PMID: 38219024DOI: https://doi.org/10.1093/jpids/piad113

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article describes a study on nirsevimab, a monoclonal antibody used to prevent RSV in infants. It shows that infants who received one dose of nirsevimab did not have worse RSV disease in their second season compared to those given a placebo. The study involved over 3,000 children and found no evidence of increased disease severity or enhanced infection due to the treatment. Nirsevimab was effective and safe for preventing serious lower respiratory tract infections caused by RSV without shifting the burden of illness to the second year of life.

---

Tags

Focus Area: Infectious Disease

Keywords: Immunization, Passive; Infant; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Respiratory Syncytial Virus, Human; Clinical Trials, Phase III as Topic; Antibodies, Monoclonal, Humanized

Emergency Management Stage: Preparedness (Prevention / Protection)

Audience: Physicians

Format: Journal Article

Media Type: Website

Institutions: Ben-Gurion University of the Negev; Johns Hopkins University; AstraZeneca; Quirónsalud Málaga Hospital; Medical University of Plovdiv; University of the Witwatersrand

Institution Types: Other; Academic; Academic; Academic; Healthcare; Academic

Language: English

Bundles: Nirsevimab Library

---

More like this

Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season 2024 · Ben-Gurion University of the Negev, Johns Hopkins University, AstraZeneca, Quirónsalud Málaga Hospital, Medical University of Plovdiv, University of the Witwatersrand Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants 2023 · Northwestern University, University of the Witwatersrand, AstraZeneca, Quirónsalud Málaga Hospital, Medical University of Plovdiv, Ben-Gurion University of the Negev Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants 2022 · Johns Hopkins University, AstraZeneca, Ben-Gurion University of the Negev, Quirónsalud Málaga Hospital

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---